Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Mitochondrial Dysfunction in Huntington's Disease; Interplay Between HSF1, p53 and PGC-1α Transcription Factors.

Intihar TA, Martinez EA, Gomez-Pastor R.

Front Cell Neurosci. 2019 Mar 19;13:103. doi: 10.3389/fncel.2019.00103. eCollection 2019.

2.

Cell-Specific Deletion of PGC-1α from Medium Spiny Neurons Causes Transcriptional Alterations and Age-Related Motor Impairment.

McMeekin LJ, Li Y, Fox SN, Rowe GC, Crossman DK, Day JJ, Li Y, Detloff PJ, Cowell RM.

J Neurosci. 2018 Mar 28;38(13):3273-3286. doi: 10.1523/JNEUROSCI.0848-17.2018. Epub 2018 Feb 28.

3.

Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease.

Chaturvedi RK, Hennessey T, Johri A, Tiwari SK, Mishra D, Agarwal S, Kim YS, Beal MF.

Hum Mol Genet. 2012 Aug 1;21(15):3474-88. doi: 10.1093/hmg/dds178. Epub 2012 May 15.

4.

Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.

Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER, Gilbert ML, Morton GJ, Bammler TK, Strand AD, Cui L, Beyer RP, Easley CN, Smith AC, Krainc D, Luquet S, Sweet IR, Schwartz MW, La Spada AR.

Cell Metab. 2006 Nov;4(5):349-62. Epub 2006 Oct 19.

5.

PGC-1α at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond.

Tsunemi T, La Spada AR.

Prog Neurobiol. 2012 May;97(2):142-51. doi: 10.1016/j.pneurobio.2011.10.004. Epub 2011 Nov 9. Review.

6.

Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.

Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D.

Cell. 2006 Oct 6;127(1):59-69.

7.

Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.

Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I.

Neurobiol Dis. 2008 Jul;31(1):80-8. doi: 10.1016/j.nbd.2008.03.010. Epub 2008 Apr 16.

8.

Meldonium improves Huntington's disease mitochondrial dysfunction by restoring peroxisome proliferator-activated receptor γ coactivator 1α expression.

Di Cristo F, Finicelli M, Digilio FA, Paladino S, Valentino A, Scialò F, D'Apolito M, Saturnino C, Galderisi U, Giordano A, Melone MAB, Peluso G.

J Cell Physiol. 2019 Jun;234(6):9233-9246. doi: 10.1002/jcp.27602. Epub 2018 Oct 26.

PMID:
30362565
9.

Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.

Martin E, Betuing S, Pagès C, Cambon K, Auregan G, Deglon N, Roze E, Caboche J.

Hum Mol Genet. 2011 Jun 15;20(12):2422-34. doi: 10.1093/hmg/ddr148. Epub 2011 Apr 14.

10.

PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function.

Tsunemi T, Ashe TD, Morrison BE, Soriano KR, Au J, Roque RA, Lazarowski ER, Damian VA, Masliah E, La Spada AR.

Sci Transl Med. 2012 Jul 11;4(142):142ra97. doi: 10.1126/scitranslmed.3003799.

11.

PGC-1α negatively regulates extrasynaptic NMDAR activity and excitotoxicity.

Puddifoot C, Martel MA, Soriano FX, Camacho A, Vidal-Puig A, Wyllie DJ, Hardingham GE.

J Neurosci. 2012 May 16;32(20):6995-7000. doi: 10.1523/JNEUROSCI.6407-11.2012.

12.

PGC-1α, mitochondrial dysfunction, and Huntington's disease.

Johri A, Chandra A, Flint Beal M.

Free Radic Biol Med. 2013 Sep;62:37-46. doi: 10.1016/j.freeradbiomed.2013.04.016. Epub 2013 Apr 19. Review.

13.

Impaired PGC-1alpha function in muscle in Huntington's disease.

Chaturvedi RK, Adhihetty P, Shukla S, Hennessy T, Calingasan N, Yang L, Starkov A, Kiaei M, Cannella M, Sassone J, Ciammola A, Squitieri F, Beal MF.

Hum Mol Genet. 2009 Aug 15;18(16):3048-65. doi: 10.1093/hmg/ddp243. Epub 2009 May 21.

14.

Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.

Hathorn T, Snyder-Keller A, Messer A.

Neurobiol Dis. 2011 Jan;41(1):43-50. doi: 10.1016/j.nbd.2010.08.017. Epub 2010 Aug 22.

15.

Gastrodia elata alleviates mutant huntingtin aggregation through mitochondrial function and biogenesis mediation.

Huang CL, Wang KC, Yang YC, Chiou CT, Tan CH, Lin YL, Huang NK.

Phytomedicine. 2018 Jan 15;39:75-84. doi: 10.1016/j.phymed.2017.12.017. Epub 2017 Dec 18.

PMID:
29433686
16.

PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease.

Taherzadeh-Fard E, Saft C, Akkad DA, Wieczorek S, Haghikia A, Chan A, Epplen JT, Arning L.

Mol Neurodegener. 2011 May 19;6(1):32. doi: 10.1186/1750-1326-6-32.

17.

Developmental alterations in motor coordination and medium spiny neuron markers in mice lacking pgc-1α.

Lucas EK, Dougherty SE, McMeekin LJ, Trinh AT, Reid CS, Cowell RM.

PLoS One. 2012;7(8):e42878. doi: 10.1371/journal.pone.0042878. Epub 2012 Aug 14.

18.

Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.

Jin J, Albertz J, Guo Z, Peng Q, Rudow G, Troncoso JC, Ross CA, Duan W.

J Neurochem. 2013 May;125(3):410-9. doi: 10.1111/jnc.12190. Epub 2013 Mar 5.

19.

The role of PGC-1α in the pathogenesis of neurodegenerative disorders.

Róna-Vörös K, Weydt P.

Curr Drug Targets. 2010 Oct;11(10):1262-9. Review.

PMID:
20840068
20.

Antioxidants in Huntington's disease.

Johri A, Beal MF.

Biochim Biophys Acta. 2012 May;1822(5):664-74. doi: 10.1016/j.bbadis.2011.11.014. Epub 2011 Nov 23. Review.

Supplemental Content

Support Center